Modality
Multispecific
MOA
HER2
Target
JAK1
Pathway
Sphingolipid
FabryCTCL
Development Pipeline
Preclinical
~May 2023
→ ~Aug 2024
Phase 1
Nov 2024
→ Sep 2025
Phase 1Current
NCT05997318
2,121 pts·CTCL
2024-11→2025-09·Terminated
2,121 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-09-156mo agoInterim· CTCL
Trial Timeline
2025Q2Q3
P1
Termina…
Catalysts
Interim
2025-09-15 · 6mo ago
CTCL
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05997318 | Phase 1 | CTCL | Terminated | 2121 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 |